| Gender Preference | None |
| Age Group | 0 - 30 years |
| Research Start Date | April 4, 2011 |
| Research End Date | April 4, 2016 |
| Principal Investigator | Ayman El-Sheikh, MD |
| Description | A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
Invasive fungal infections are infections caused by organisms called fungi that enter the blood stream and can then spread to different organs in the body. Chemotherapy used to treat AML severely reduces the body’s natural infection fighting ability. Preventing invasive fungal infections due to chemotherapy is therefore very important for the study treatment success of people with AML.
This study is organized by Children’s Oncology Group (COG). The overall goal of this study is to compare the effects of 2 antifungal drugs: caspofungin and fluxonazole on people getting treatment for AML. On this study, you will either get caspofungin or fluconazole. You will not get both drugs.
Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Approximately 550 people will be enrolled worldwide. |
| Contact Info | Julie de la Garza, RN (319) 36-3749 |
| Keywords | span itemProp='description'>ACCL0933 ; Acute Myeloid Leukemia (AML) ; cancer ; Caspofungin ; Children ; Fluconazole ; pediatric ; |